Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12721MR)

This product GTTS-WQ12721MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12721MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14749MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ9422MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ14652MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ10929MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ8729MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ5489MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ10239MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ1755MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW